Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade(®) to Remsima(®)? An Observational Study

Background: Since the late ‘90s, infliximab (Remicade(®)) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima(®) were introduced in clinical practice. Aim: To investigate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Laixi, van Bilsen, K., Schreurs, M. W. J., van Velthoven, M. E. J., Missotten, T. O., Thiadens, A. A. H. J., Kuijpers, R. W. A. M., van Biezen, P., Dalm, V. A. S. H., van Laar, J. A. M., Hermans, M. A. W., Dik, W. A., van Daele, P. L. A., van Hagen, P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424016/
https://www.ncbi.nlm.nih.gov/pubmed/32850911
http://dx.doi.org/10.3389/fmed.2020.00418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424016/
https://www.ncbi.nlm.nih.gov/pubmed/32850911
http://dx.doi.org/10.3389/fmed.2020.00418

Ejemplares similares